Cabaletta Bio, Inc.
CABA
$1.21
$0.054.31%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 39.40% | 38.41% | 67.41% | 34.42% | 130.65% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 45.96% | 77.02% | 90.55% | 65.32% | 41.98% |
| Operating Income | -45.96% | -77.02% | -90.55% | -65.32% | -41.98% |
| Income Before Tax | -56.02% | -86.22% | -90.53% | -57.99% | -33.10% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -56.02% | -86.22% | -90.53% | -57.99% | -33.10% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -56.02% | -86.22% | -90.53% | -57.99% | -33.10% |
| EBIT | -45.96% | -77.02% | -90.55% | -65.32% | -41.98% |
| EBITDA | -46.06% | -78.14% | -92.35% | -66.58% | -43.06% |
| EPS Basic | -41.30% | -65.49% | -50.95% | -13.60% | 11.54% |
| Normalized Basic EPS | -41.32% | -65.53% | -50.97% | -13.60% | 11.54% |
| EPS Diluted | -41.30% | -65.73% | -51.35% | -13.33% | 11.54% |
| Normalized Diluted EPS | -41.32% | -65.53% | -50.97% | -13.60% | 11.54% |
| Average Basic Shares Outstanding | 10.41% | 12.53% | 26.22% | 39.08% | 50.46% |
| Average Diluted Shares Outstanding | 10.41% | 12.53% | 26.22% | 39.08% | 50.46% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |